Clinical TrialsPatient enrollment for ARTEMIS, the first P3 study for ixo-vec, is ahead of schedule, indicating strong interest and potential success in the clinical trial.
Efficacy And SafetyIxo-vec has demonstrated paradigm shifting potential in the treatment of neovascular or wet AMD patients with its differentiated injection durability profile, and safety and tolerability with reliable inflammation management.
Funding And Financial StrategyThe $125.7M in cash and equivalents is anticipated to fund operations into the second half of 2025, supporting the ongoing pivotal program.